Why Alto Neuroscience, Inc.’s (ANRO) Stock Is Up 5.20%
As of Monday, August 17, Alto Neuroscience, Inc.’s ANRO share price has surged by 5.20%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson’s disease for patients with Parkinson’s disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Commentary & Analysis
Why Alto Neuroscience, Inc.’s (ANRO) Stock Is Down 6.69%
As of Friday, August 14, Alto Neuroscience, Inc.’s ANRO share price has dipped by 6.69%, which has investors questioning if this is right time to buy.Michael Rose
Why Alto Neuroscience, Inc.’s (ANRO) Stock Is Up 9.00%
As of Thursday, August 13, Alto Neuroscience, Inc.’s ANRO share price has surged by 9.00%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Alto Neuroscience, Inc.’s (ANRO) Stock Is Down 5.90%
As of Friday, July 31, Alto Neuroscience, Inc.’s ANRO share price has dipped by 5.90%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Alto Neuroscience, Inc.’s (ANRO) Stock Is Down 6.26%
As of Friday, July 10, Alto Neuroscience, Inc.’s ANRO share price has dipped by 6.26%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | ANRO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,337.0 | $646.4 | 49% |
|
| Shares Out (Mil) | 42.8 | 43.4 | 44% |
|
| Institutional Ownership | 96.5% | 83.9% | 70% |
|
| Float (Mil) | 29.7 | 45.7 | 36% |
|
| Beta | 1.09 | 0.73 | 65% |
|
| Avg Daily Volume (000s) | 417 | 299 | 57% |
|
| Price Change (52-week) |
775.8% | 67.8% | 100% |
|
| Growth | ANRO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 6 | 7 | |
| Current EPS | ($0.703) | ($2.922) | ($3.286) | |
| Month Ago EPS | ($0.798) | ($3.145) | ($3.433) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.798) | ($3.145) | ($3.433) | |
| Year/Year Chg | 8.8% | 33.3% | 53.5% | |
| Financials | ANRO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $304 | na |
|
| Net Income (TTM) (Mil) | ($84) | ($11) | 12% |
|
| EPS (TTM) | ($2.379) | ($0.700) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($68) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $96 | $6 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $18 | $6 | 32% |
|
| Enterprise Value (Q1) (Mil) | $1,041 | $524 | 41% |
|
| Valuation | ANRO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.45 | 2.72 | 81% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ANRO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.1% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (40.9%) | (24.1%) | 14% |
|
| ROE | (49.2%) | (21.4%) | 15% |
|
| Liabilities to Assets | 13.7% | 32.6% | 8% |
|
| F-Score | 2 | 3 | 7% |
|
Passing Stock Screens
As of 9/9/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.4% |
| +/- S&P 500: | +13.9 |
GURU STRATEGY
Lakonishok Screen
Factors: Value, Momentum
Identifying stocks trading at a discount to their industry norms but showing recent price strength and upward earnings revisions.
| Performance Since Inception: | 13.1% |
| +/- S&P 500: | +5.6 |
